Conference item
Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
- Abstract:
- Vedolizumab is a gut-selective antibody to α4β7 integrin approved for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) in adult patients. Only 3% of patients in pivotal trials of vedolizumab were aged 65–80 years and patients aged >80 years were excluded. We analysed post marketing safety data to investigate whether older patients reported a different safety profile with vedolizumab compared with younger patients.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 177.6KB, Terms of use)
-
- Publisher copy:
- 10.1093/ecco-jcc/jjx180.588
Authors
- Publisher:
- Oxford University Press
- Host title:
- Journal of Crohn's and Colitis
- Journal:
- 13th Congress of the European Crohn's and Colitis Organisation (ECCO 2018) More from this journal
- Volume:
- 12
- Issue:
- supplement_1
- Pages:
- S111
- Publication date:
- 2018-01-16
- Acceptance date:
- 2017-12-22
- DOI:
- EISSN:
-
1876-4479
- ISSN:
-
1873-9946
- Pubs id:
-
pubs:844395
- UUID:
-
uuid:b8f7c7b8-a0fd-4fca-a419-0845ea0a8b23
- Local pid:
-
pubs:844395
- Source identifiers:
-
844395
- Deposit date:
-
2018-04-27
Terms of use
- Copyright holder:
- European Crohn’s and Colitis Organisation
- Copyright date:
- 2018
- Notes:
- Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected] This is the accepted manuscript version of the article. The final version is available online from Oxford University Press at: http://dx.doi.org/10.1093/ecco-jcc/jjx180.588 This paper was presented at the 13th Congress of the European Crohn's and Colitis Organisation (ECCO 2018)
If you are the owner of this record, you can report an update to it here: Report update to this record